Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10914550 | Molecular Oncology | 2016 | 10 Pages |
Abstract
Having established assay sensitivity in mouse models, we identified 26 miRNAs that were elevated in a stage dependent manner in a pilot study of plasma from SCLC patients (n = 16) compared to healthy controls (n = 11) that were also elevated in the mouse models. We selected a smaller panel of 10 previously reported miRNAs (miRs 95, 141, 200a, 200b, 200c, 210, 335#, 375, 429) that were consistently elevated in SCLC, some of which are reported to be elevated in other cancer types. Using a multiplex qPCR assay, elevated levels of miRNAs across the panel were also observed in a further 66 patients with non-small cell lung, colorectal or pancreatic cancers. The utility of this circulating miRNA panel as an early warning of tumor progression across several tumor types merits further evaluation in larger studies.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alastair Greystoke, Mahmood Ayub, Dominic G. Rothwell, Dan Morris, Deborah Burt, Cassandra L. Hodgkinson, Christopher J. Morrow, Nigel Smith, Kyaw Aung, Juan Valle, Louise Carter, Fiona Blackhall, Caroline Dive, Ged Brady,